Feb 14, 2014 by Brian Orelli, PhD3 Companies Facing FDA Approval: Chelsea, MannKind, and DurataA video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.
Feb 3, 2014 by Brian Orelli, PhDNot What the Obesity Doctor OrderedArena Pharmaceuticals announces dismal fourth-quarter sales. Can Aetna help VIVUS turn things around?
Feb 2, 2014 by Brian Orelli, PhDCan Biotech Dominate for a 4th Year in a Row?Only if investors continue to accept risk.
Feb 1, 2014 by Brian Orelli, PhDAmgen Goes 6 for 6 Fighting CholesterolAmgen's evolocumab looks good so far and has a lead on Regeneron Pharmaceuticals, Sanofi, Alnylam, and the rest of the companies developing PCSK9 inhibitors.
Jan 31, 2014 by Brian Orelli, PhD3 One-Drug Biotech Wonders: Seattle Genetics, Medivation, and RegeneronFor Seattle Genetics, Medivation, and Regeneron, one drug is enough.
Jan 31, 2014 by Brian Orelli, PhDAbbVie Headed to FDA, Clash With Gilead SetAbbVie and Enanta Pharmaceuticals' hepatitis C drug cocktail is much better than older medications from Merck and Vertex Pharmaceuticals and comparable to Gilead Sciences' new cocktail.
Jan 31, 2014 by Brian Orelli, PhDA Short-Lived FDA Approval PopVanda Pharmaceuticals gained FDA approval for Hetlioz, but investors appear worried about how the drug will sell. Arena Pharmaceuticals and VIVUS are good examples of other biotechs that haven't lived up to their expectations.
Jan 30, 2014 by Brian Orelli, PhDVertex Investors Rightfully Ignore EarningsVertex Pharmaceuticals is in transition to a cystic fibrosis company. Expectations of new drugs from Gilead, Johnson & Johnson, Bristol-Myers, and others have decimated hepatitis C drug sales.
Jan 29, 2014 by Brian Orelli, PhDThe Problem With Obamacare's 9 Million Enrollment NumberThe State of the Union Number was accurate but not as important as this unknown figure.
Jan 28, 2014 by Brian Orelli, PhDMedivation Still PrevailingNew data on Medivation's Xtandi still makes it look better than Johnson & Johnson's Zytiga and Dendreon's Provenge.
Jan 27, 2014 by Brian Orelli, PhDWill the FDA Approve Vanda's Hetlioz?Vanda Pharmaceuticals faces the FDA firing squad. Will it have similar fare to Sarepta Therapeutics and InterMune?
Jan 27, 2014 by Brian Orelli, PhDChecking in on OPKO Long After J.P. Morgan EndsThe health-care conference might be over, but you can still watch presentations from OPKO Health and others.
Jan 27, 2014 by Brian Orelli, PhDBreaking Down Geron Corporation's Stock-Tanking DisclosureIt wasn't as bad as Geron's investors made it out to be; Competitor Incyte wasn't even up on the news.
Jan 16, 2014 by Brian Orelli, PhDHandicapping Amarin's DelayAmarin gets another delay from the FDA. Thanks AbbVie and Merck.
Jan 16, 2014 by Brian Orelli, PhDA Big Day for Duchenne Muscular Dystrophy DrugmakersSarepta Therapeutics and Prosensa shares increase dramatically with separate data releases. Did GlaxoSmithKline make a mistake letting Prosensa go?
Jan 15, 2014 by Brian Orelli, PhDObamacare Enrollment: Does This Number Doom Health Care Reform?It's not the number of people, but their age breakdown.
Jan 13, 2014 by Brian Orelli, PhDGSK Leaves Prosensa HangingGlaxoSmithKline hands back rights to DMD program to Prosensa, which could affect rival Sarepta Therapeutics.
Jan 10, 2014 by Brian Orelli, PhDMannKind's Pit Stop on the Road to ApprovalMannKind's inhaled insulin Afrezza will face an advisory committee meeting in April.
Jan 10, 2014 by Brian Orelli, PhD516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely OutcomeIntercept Pharmaceuticals jumps on phase 2 data for obeticholic acid in patients with NASH.
